Blood

Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors

Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pancreatic cancer, Blood, LinkedIn, Metastasis, Cancer, Travel, Annual report, Doctor of Philosophy, Drug development, Â, Neoplasm, Twitter, Security (finance), U.S. Securities and Exchange Commission, Kirom Bukhoroi, Patient, NASDAQ, Founder, Private Securities Litigation Reform Act, Terminology, SEC, Forward-looking statement, Primary tumor, Company, Clinical trial, Trial of the century, Tissue, Multimedia, Form 10-K, PFS, Securities Exchange Act of 1934, Pharmaceutical industry, Medical imaging, Vaccine
Monday, October 25, 2021 - 12:03pm

We are very proud of the results we achieved with KiroVax/BSK01 in addressing advanced metastatic pancreatic cancer.

Key Points: 
  • We are very proud of the results we achieved with KiroVax/BSK01 in addressing advanced metastatic pancreatic cancer.
  • As we did with KiroVax/BSK01, we expect to be able to also progress Kiromics CAR-T therapies to the clinical arena.
  • Metastasis is the spread of cancer cells from the place where they first formed to another part of the body.
  • More information on this Phase 1 clinical trial may be found on the Companys website.

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

Vitamin, Tell, Compliance, Research, Chest pain, Blood, LinkedIn, Anticoagulant, Bruise, Public expenditure, Mission statement, Penis, Natural borrowing limit, Patient, Private Securities Litigation Reform Act, NASDAQ, Bleeding, System, Peyronie's disease, U.S. Securities and Exchange Commission, Back pain, Life, Allergy, Spasms, Muscle, Risk, Defecation, Legislation, Medication, Tenderness, Poultry, Pharmaceutical industry, Birth control
Monday, October 25, 2021 - 12:00pm

DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.

Key Points: 
  • Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.
  • Before receiving XIAFLEX, tell your healthcare provider if youhave had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

Vitamin, Tell, Compliance, Research, Chest pain, Blood, LinkedIn, Anticoagulant, Bruise, Public expenditure, Mission statement, Penis, Natural borrowing limit, Patient, Private Securities Litigation Reform Act, NASDAQ, Bleeding, System, Peyronie's disease, U.S. Securities and Exchange Commission, Back pain, Life, Allergy, Spasms, Muscle, Risk, Defecation, Legislation, Medication, Tenderness, Poultry, Pharmaceutical industry, Birth control
Monday, October 25, 2021 - 12:00pm

DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.

Key Points: 
  • Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.
  • Before receiving XIAFLEX, tell your healthcare provider if youhave had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

Neurology, NEW, MD, Research, Peripheral nervous system, Diagnosis, University, Blood, Disease, Industry, Vii, Diabetic cardiomyopathy, CNS, Twitter, Patient, Ix, Private Securities Litigation Reform Act, Hereditary neuropathy with liability to pressure palsy, Applied psychology, Neuromuscular medicine, Xi, U.S. Securities and Exchange Commission, Disability, ID, Eye, Diabetic retinopathy, Government, Ribosomal s6 kinase, Sorbitol, Forward-looking statement, Patent, Intention, COVID-19, Lists of diseases, Investor relations, Metabolism, Nasdaq, ARI, Therapy, PMM2-CDG, Division, Motor neuron, Central nervous system, GLOBE, Doctor of Philosophy, Heart, Pharmaceutical industry
Monday, October 25, 2021 - 12:00pm

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.

Key Points: 
  • Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons.
  • Patients with SORD Deficiency have 100 times higher sorbitol concentration in their blood compared with unaffected individuals.
  • In a pilot open-label study in 8 SORD Deficiency patients, AT-007 reduced blood sorbitol levels by approximately 66% from baseline through 30 days of treatment.
  • Applied Therapeutics will host a conference call today, Monday, October 25, 2021, at 8:30 a.m. Eastern Time, to discuss data from a pilot trial of AT-007 in SORD deficiency.

Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma

Safety, Șaeș, Compliance, Recurrence, Blood, Skin cancer, Cancer, Tongue, Neoplasm, PRV, Patient, Deleted in Colorectal Cancer, FDA, Squamous cell carcinoma, SCC, Risk, Cisplatin, Lymph, PK, Skin, Company, Clinical trial, HNSCC, Lip, NDA, Needle, Infrared spectroscopy correlation table, Toxicity, GLOBE, Incidence, Treatment, Pharmaceutical industry, Dentistry
Friday, October 22, 2021 - 6:39pm

PRV111 showed a favorable safety profile with no severe adverse events (SAEs).

Key Points: 
  • PRV111 showed a favorable safety profile with no severe adverse events (SAEs).
  • Reported treatment emergent adverse events (TEAEs) were mild or moderate in severity, and no dose-limiting toxicities (DLTs) were observed.
  • The clinical trial design was Open-Label, Single-Arm Safety, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV111 in subjects with Head and Neck Squamous Cell Carcinoma.
  • Squamous cell carcinoma (SCC) is cancer of the squamous cells - thin and flat cells that line the epithelia.

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Safety, Cytokine release syndrome, MD, Blood, Shock, RJX, Cancer, Inflammation, Disease, CRS, NIPPV, Patient, Private Securities Litigation Reform Act, Part, FDA, Sepsis, Multiple organ dysfunction syndrome, Acute respiratory distress syndrome, SEC, Communication, Adult, Forward-looking statement, LLC, Standard of care, Clinical trial, CEO, COVID-19, Health, PAD, Risk, DSMB, Pneumonia, Pharmaceutical industry
Friday, October 22, 2021 - 1:30pm

Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.

Key Points: 
  • Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.
  • Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • This FDA-approved controlled clinical trial is aimed at evaluating the efficacy and safety of RJX in side-by-side comparison with a placebo as an adjunct to standard of care in hospitalized COVID-19 patients.
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

Biotechnology, Genetics, Health, Clinical Trials, EGFR, Breast cancer, PIK3CA, Biotechnology, Diagnosis, Blood, PCR, Budget, Disease, Health Innovation Manchester, Genomics, Colorectal cancer, NGS, BRAF, Patient, Transport, FDA, FGFR, Large-cell lung carcinoma, List of life sciences, Weather, RNA, Molecular diagnostics, U.S. Securities and Exchange Commission, Life, Senior, Annual report, CityLab, Marketing, Protein, Central business district, COVID-19, Growth, Precision medicine, Polymerase chain reaction, Solution, Health, Knowledge, Lists of disasters, Automation, Heart, Squamous cell carcinoma, George C. Marshall European Center for Security Studies, Global Health Innovative Technology Fund, KRAS, DNA, Pharmaceutical industry, Warehouse
Friday, October 22, 2021 - 11:00am

QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

Key Points: 
  • QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
  • The move into the new facility will help us write the next chapter of this success story.
  • Health Innovation Manchester unites the regions spectrum of public, academic and clinical resources.
  • It is meant to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

ImmunoTek Bio Centers Opens 50th Location

Research, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Plasmapheresis, Dementia, Research, Patient, Blood, Lists of diseases, Vaccine, Cancer, Plasma, CEO, Degenerative disease, COVID-19, Pharmaceutical industry, Medical device
Friday, October 22, 2021 - 12:10am

The largest independent plasma donation center operator in the country is marking a major milestone this week, as ImmunoTek Bio Centers opens its 50th plasma donation center in the U.S.

Key Points: 
  • The largest independent plasma donation center operator in the country is marking a major milestone this week, as ImmunoTek Bio Centers opens its 50th plasma donation center in the U.S.
  • Since its creation in 2013, Louisiana-based ImmunoTek Bio Centers has completed more than six million donations, providing much-needed plasma manufactured into plasma protein therapies and vaccines to treat immune disorders, rare diseases, burn victims, cancer patients, and many other illnesses.
  • The companys 50th center is in Pueblo, Colorado and comes at a time when plasma donations are in great demand.
  • ImmunoTek has centers operating in 12 states, with 30 centers in progress and plans for more than 60 additional sites over the next three years.

On Pfizer CEO Albert Bourla’s Birthday, Medical Students and Activists from Health GAP, Rise and Resist, CPD Action and More Protest at His Home to Demand Equitable Global Access to COVID-19 Vaccines

Revelation, Blood, World Trade, Vaccine, COVID-19 vaccine, World, TRIPS, Rise and Resist, Public Citizen, Thought, Heel, CEO, COVID-19, Big Pharma, Death, COVID, Population, GLOBE, Reading, White House, Pharmaceutical industry
Thursday, October 21, 2021 - 10:12pm

This is the third time activists have demanded global access to COVID-19 vaccines at the doorsteps of key duty-bearers.

Key Points: 
  • This is the third time activists have demanded global access to COVID-19 vaccines at the doorsteps of key duty-bearers.
  • Vinay Krishnan, National Field Organizer, CPD Action , said: Today is Albert Bourlas birthday, so we decided to pay him a house visit.
  • Of all the lives lost because Pfizer, Moderna, and yes, President Biden, refuse to take action to end vaccine apartheid.
  • We need to put people over profits and take global action to end this global crisis.

Einstein-Developed Treatment Strategy May Lead to HIV Cure

Head, Biochemistry, NIH, Twitter, Partnership, Selective, Degenerative disease, Liver disease, University Hospital (Newark, New Jersey), JCI, National, Clinical trial, Ageing, Medical College of Wisconsin, Multimedia, Program, Autoimmune disease, Investor, HIV, Infection, Albert Einstein College of Medicine, Research, Blood, CMV, Blog, HIV/AIDS research, Cytomegalovirus, Biophysics, Teaching hospital, AIDS, Hospital, College, Virus, Journal, Protein, Immunology, Weill Cornell Medicine, Microbiology, Diabetes, Pediatrics, Student, Technology, College of Medicine (UK), Cancer, Macromolecule, US, ART, Patient, Multiple sclerosis, YouTube, Medical college, Doctor of Philosophy, Neuroscience, Cell, Vaccine
Thursday, October 21, 2021 - 6:06pm

"Although ART works remarkably well at keeping HIV in check indefinitely, it is a stalemate and not a checkmate," said co-corresponding author Harris Goldstein, M.D.

Key Points: 
  • "Although ART works remarkably well at keeping HIV in check indefinitely, it is a stalemate and not a checkmate," said co-corresponding author Harris Goldstein, M.D.
  • "It's unlikely that any treatment strategy can remove all latently infected T cells," said Dr. Goldstein.
  • "Our goal with synTac is a 'functional cure,' in which the powerful immune response induced by synTac suppresses HIV to undetectable levels even after they discontinue ART."
  • Next, the researchers intravenously injected synTacs specific for HIV or CMV into virus-infected mice with "humanized" immune systems that permit infection by viruses affecting people, such as HIV and CMV.